Key facts
- It has raised $6.6M; the latest was Early Stage VC in May 2024.
- Notable investors include Mitsubishi UFJ Capital, The University of Tokyo Edge Capital, Keio Innovation Initiative, Hiroshima Venture Capital, Osaka University Venture Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for PURMX Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for PURMX Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PURMX Therapeutics
Developer of a silver bullet and nucleic acid drug intended for malignant pleural mesothelioma. The company creates innovative nucleic acid drugs to save patients suffering from intractable diseases and offers therapies for cancer treatment, enabling healthcare professionals with drugs using small ribonucleic acid that have become deficient in cells.
- Sector
- Healthcare
- HQ
- Hiroshima, Japan
- Founded
- 2021
- Employees
- 9
- Website
- purmx.com/
- Ownership
- Privately Held (backing)
PURMX Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PURMX Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PURMX Therapeutics in its N-PORT filings yet. We sweep new filings monthly.